Results 201 to 210 of about 27,341 (230)

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.

The Lancet, 2022
BACKGROUND Drug combinations rather than increasing doses of one drug can achieve greater efficacy and lower risks. Thus, as an alternative to high-intensity statin monotherapy, moderate-intensity statin with ezetimibe combination therapy can lower LDL ...
Byeong‐Keuk Kim, S. Hong, Yong-Joon Lee, S. Hong, K. Yun, B. Hong, J. Heo, S. Rha, Yun‐Hyeong Cho, Seung-Jun Lee, C. Ahn, Jung‐Sun Kim, Y. Ko, D. Choi, Y. Jang, M. Hong   +15 more
semanticscholar   +1 more source

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.

Journal of the American College of Cardiology, 2023
BACKGROUND The routine use of high-intensity statins should be considered carefully in elderly patients because of their higher risk of intolerance or adverse events.
Sang-Hyup Lee, Yong-Joon Lee, J. Heo, S. Hur, H. Choi, Kyung-Jin Kim, Ju Han Kim, K. Park, Jung Hee Lee, Y. Choi, Seung-Jun Lee, Sung‐Jin Hong, C. Ahn, Byeong‐Keuk Kim, Y. Ko, D. Choi, M. Hong, Y. Jang, Jung‐Sun Kim   +18 more
semanticscholar   +1 more source

PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients.

Progress in cardiovascular diseases, 2023
Statins are first-line therapy for treating dyslipidemia because of their low-density lipoprotein cholesterol (LDL-C) lowering efficacy, superior event-reduction data and unrivaled cost-effectiveness.
S. P. Gunta, J. O’Keefe, Evan L. O’Keefe, C. Lavie   +3 more
semanticscholar   +1 more source

Safety and efficacy of ezetimibe: A meta-analysis

International Journal of Cardiology, 2015
The addition of ezetimibe to statin therapy has been widely demonstrated to significantly reduce low-density lipoprotein cholesterol levels. However, the efficacy of ezetimibe in reducing CV events and its safety has been less investigated.
Gianluigi Savarese, Gaetano Maria De Ferrari, Giuseppe M C Rosano   +2 more
exaly   +2 more sources

Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

The Lancet
BACKGROUND Reducing LDL cholesterol prevents atherosclerotic cardiovascular disease (ASCVD) events. The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose combination (FDC) of obicetrapib, a CETP inhibitor, and ...
Ashish Sarraju, Danielle Brennan, Kierstyn Hayden, Amanda Stronczek, Anne C Goldberg, Erin D. Michos, Darren K. McGuire, Denise Mason, Grace Tercek, Stephen J. Nicholls, D. Kling, Annie L Neild, John Kastelein, Michael H. Davidson, M. Ditmarsch, Steven E. Nissen   +15 more
semanticscholar   +1 more source

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.

Journal of the American College of Cardiology, 2021
BACKGROUND The 2018 U.S. cholesterol management guideline recommends additional lipid-lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL despite maximally ...
K. Oyama, R. Giugliano, M. Blazing, Jeong-Gun Park, A. Tershakovec, M. Sabatine, C. Cannon, E. Braunwald   +7 more
semanticscholar   +1 more source

Repurposing ezetimibe as a neuroprotective agent in a rotenone-induced Parkinson's disease model in rats: Role of AMPK/SIRT-1/PGC-1α signaling and autophagy.

International Immunopharmacology
As a severe neurological disorder, Parkinson's disease (PD) is distinguished by dopaminergic neuronal degeneration in the substantia nigra (SN), culminating in motor impairments.
Wessam H. Elesawy, Ayman E. El‐Sahar, R. H. Sayed, Ahmed M. Ashour, Shuruq E. Alsufyani, H. Arab, Esraa A Kandil   +6 more
semanticscholar   +1 more source

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome

FEBS Letters, 2007
Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome characterized by dislipidemia and insulin resistance. We hypothesized that ezetimibe, an inhibitor of NPC1L1, improves these metabolic disorders in Zucker obese fatty ...
Akio Kawakami, Mitsuyo Okazaki, Masayuki Yoshida   +2 more
exaly   +2 more sources